RAPP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rapport Therapeutics Inc (RAPP) is not a strong buy for a beginner investor with a long-term horizon at this moment. Despite positive analyst ratings and promising clinical data, insider selling, lack of significant hedge fund interest, and weak financial performance suggest caution. The stock may be worth monitoring for future developments, but it is not an immediate buy.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral, and moving averages are bullish. However, the stock is trading below the pivot level (37.152) in pre-market, with key support at 34.402 and resistance at 39.902.
Analyst coverage from Raymond James with a Strong Buy rating and a $66 price target, citing potential catalysts in RAP-219's Phase 2 readout for bipolar mania.
Positive clinical data showing a 90% reduction in seizures for epilepsy patients.
Insider selling has increased significantly (3094.14% over the last month).
Third Rock Ventures plans to sell a substantial number of shares, indicating potential lack of confidence.
Weak financial performance with no revenue and negative net income.
In Q4 2025, the company reported no revenue, a net loss of $33.76 million (though improved YoY by 68.98%), and an EPS of -0.72 (improved by 26.32% YoY). The company is not yet profitable.
Analysts are optimistic with Strong Buy and Overweight ratings, and price targets ranging from $43 to $66. They highlight RAP-219's potential in both focal onset seizures and bipolar mania as key growth drivers.
